Table 6.
Adverse events reported by survey participants approximately three months after the third round of mass drug administration, Egypt
| Characteristic | No. | %* | P | Odds ratio (95% confidence interval) |
|---|---|---|---|---|
| Adverse event | ||||
| Dizziness | 362 | 80.4 | ||
| Fatigue | 53 | 11.8 | ||
| Nausea and vomiting | 13 | 2.9 | ||
| Fever | 10 | 1.8 | ||
| Other (scrotal or chest pain) | 12 | 0.8 | ||
| Duration | ||||
| Few hours | 328 | 72.9 | ||
| 1 day | 89 | 19.8 | ||
| > 1 day | 33 | 7.3 | ||
| No. | %† | |||
| Sex | ||||
| M | 157 | 13.9 | 0.001 | 1.78 (1.4–2.2) |
| F | 293 | 22.4 | ||
| Age, years | ||||
| < 30 | 206 | 18.6 | 0.8 | |
| ≥ 30 | 244 | 18.4 | ||
*
Percentages of persons with any adverse event that reported different symptoms.
†
Percentages of all persons interviewed who reported adverse events after taking MDA (by sex and age). Note that noncompliant persons who did not receive mass drug administration were not included in this analysis.